This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF. USD 39.95 Prices may be subject to local taxes which are calculated during checkout Fig. 1: Cumulative incidence of HHV-6B encephalitis.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Junya Kanda
Development of a stacked ensemble model for risk stratification of chronic GVHD after allogeneic HSCT: Japanese nation-wide cohort study
|
By Makoto Iwasaki, Junya Kanda, Fumihiko Kimura, Yoshiko Atsuta, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Tetsuya Nishida, Yuta Katayama, Masatsugu Tanaka, Satoshi Yoshihara, Yoshinobu Kanda, Masashi Sawa, Makoto Onizuka, Moeko Hino, Koji Kawamura, Ken Tabuchi, Akifumi Takaori-Kondo, Sachiko Seo, Taro Tochigi
|
Frontiers in Immunology
Abstract Effective risk stratification is vital for donor selection and treatment strategies in allogeneic hematopoietic stem cell transplantation (HSCT). We developed a prediction model for mid- to long-term outcomes after HSCT using a stacked ensemble model (SEM).
Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis
|
By Yoshimitsu Shimomura, Hiroki Hosoi, Kyoko Fuse, Shinsuke Kusakabe, Satoshi Yoshihara, Ken Takase, Toshihiro Matsukawa, Toru Izumi, Keisuke Kataoka, Naoyuki Uchida, Nobuhiro Kanemura, Senji Kasahara, Hiroatsu Iida, Jun Ishikawa, Hirohisa Nakamae, Kazunori Imada, Koji Kawamura, Makoto Onizuka, Junya Kanda, Yoshiko Atsuta, Hidehiro Itonaga, Kamma Shiraishi, Machiko Fujioka
|
Nature
Verified
To the Editor: Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias, with a risk of progression to acute myeloid leukemia [1]. Although allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative treatment, relapse after HSCT occurs in ~15–60% of patients [2] and remains a major clinical challenge. A second HSCT is a therapeutic option for these patients.
Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes
|
By Junya Kanda, Keiichiro Hattori, Nobuhiro Hiramoto, Nobuhiro Kanemura, Senji Kasahara, Mitsumasa Watanabe, Satoshi Yoshihara, Michiko Ichii, Nobuo Sezaki, Takeshi Maeda, Ko Sasaki, Toshiyuki Kitano, Tadakazu Kondo, Mamiko Sakata-Yanagimoto, Akifumi Takaori-Kondo, Seishi Ogawa, Yasuhito Nannya, Masataka Sakashita, Masaaki Tsuji, Yasuko Miyahara
|
Nature
Verified
Dear Editor, Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by clonal hematopoiesis, recurrent genetic abnormalities, myelodysplasia, and a risk of progression to acute myeloid leukemia (AML) [1,2,3]. Despite the availability of various therapeutic interventions such as chemotherapy and hypomethylating agents (HMAs) to delay disease progression, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy [1].
Conditioning-adapted methotrexate in cord blood transplantation for high-risk acute myeloid leukemia: a nationwide Japanese cohort analysis
|
By Satoshi Yamasaki, Masamitsu Yanada, Tomomi Toubai, Kaito Harada, Masatsugu Tanaka, Makoto Onizuka, Tetsuya Nishida, Norimichi Hattori, Satoshi Takahashi, Masashi Sawa, Yuta Katayama, Toshiro Kawakita, Jun Ishikawa, Masahito Tokunaga, Koichi Onodera, Koji Nagafuji, Hideki Nakasone, Fumihiko Ishimaru, Junya Kanda, Yoshiko Atsuta, Takaaki Konuma, Toru Izumi
|
Nature
Verified
Abstract Allogeneic cord blood transplantation (CBT) is a curative option for adults with high-risk acute myeloid leukemia, but outcomes depend on conditioning intensity and graft-versus-host disease (GVHD) prophylaxis. We analyzed 1311 adults undergoing first single-unit CBT with six protocol-defined myeloablative or reduced-intensity regimens and uniform calcineurin inhibitor plus short-course methotrexate (MTX) at high, standard, or low doses.
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
|
By Yotaro Ochi, Markus Liew-Littorin, Yasuhito Nannya, Sofia Bengtzén, Benedicte Piauger, Stefan Deneberg, Martin Jädersten, Vladimir Lazarevic, Jörg Cammenga, Anna Robelius, Lovisa Wennström, Emma Rie Olander, Senji Kasahara, Nobuhiro Hiramoto, Nobuhiro Kanemura, Nobuo Sezaki, Maki Sakurada, Makoto Iwasaki, Junya Kanda, Yasunori Ueda, Satoshi Yoshihara, Tom Erkers, Nona Struyf, Yu Watanabe, Masanori Motomura, Masahiro Nakagawa, Ryunosuke Saiki, Hidehito Fukushima, Koji Okazaki, Suguru Morimoto, Akinori Yoda, Rurika Okuda, Shintaro Komatsu, Guoxiang Xie, Albin Österroos, Ayana Kon, Lanying Zhao, Yuichi Shiraishi, Takayuki Ishikawa, Satoru Miyano, Kotoe Katayama, Seiya Imoto, Shuichi Matsuda, Akifumi Takaori-Kondo, Hiroyuki Aburatani, Hiroshi Suzuki, Olli Kallioniemi, Gunnar Juliusson, Martin Höglund, Sören Lehmann, Seishi Ogawa
|
Nature
Verified
Abstract Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively.
Prognostic factors and a novel scoring system for allogeneic hematopoietic stem cell transplantation in patients aged 70 years or older: a nationwide registry analysis in Japan
|
By Noriyoshi Yoshinaga, Yoshitaka Inoue, Tomomi Toubai, Naoyuki Uchida, Yasufumi Uehara, Naoyuki Anzai, Atsushi Wake, Noriko Doki, Masahito Tokunaga, Tetsuya Eto, Norimichi Hattori, Masatsugu Tanaka, Mitsumasa Watanabe, Tomohiko Kamimura, Koji Kawamura, Takahiro Fukuda, Marie Ohbiki, Yoshiko Atsuta, Hideki Nakasone, Kimikazu Yakushijin, Junya Kanda, Asami Kataoka, Kazuto Ogura, Toshio Wakayama
|
Nature
Verified
Abstract Despite recent advances, data on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients aged ≥70 years remain limited. We identified prognostic factors and developed a risk score to guide transplant eligibility. Using the Japanese Transplant Registry Unified Management Program, we retrospectively analyzed 929 patients aged ≥70 years who underwent their first allo-HSCT for hematologic malignancies between 2000 and 2022.
Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patients
|
By Ryu Yanagisawa, Itaru Kato, Hiromi Hayashi, Shin-ichiro Fujiwara, Noriko Doki, Yuta Hasegawa, Shinichi Kako, Yasuhiko Shibasaki, Satoshi Yoshihara, Nobuhiro Hiramoto, Takahiro Fukuda, Naoyuki Uchida, Hirohisa Nakamae, Tetsuya Eto, Koji Nagafuji, Mamiko Sakata-Yanagimoto, Masatsugu Tanaka, Katsutsugu Umeda, Yoshinobu Kanda, Ken Tabuchi, Yoshiko Atsuta, Junya Kanda, Hideki Nakasone
|
Nature
Verified
Abstract Comparative data on alternative donor platforms in adolescent and young adult (AYA) allogeneic hematopoietic cell transplantation (HCT) are limited. We conducted a nationwide retrospective registry study in Japan comparing unrelated umbilical cord blood transplantation (UCBT), haploidentical transplantation without post-transplant cyclophosphamide (non-PTCy-haplo), and PTCy-based haploidentical transplantation (PTCy-haplo).
Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era
Abstract Ibrutinib, a Bruton tyrosine kinase inhibitor, has improved outcomes for patients with relapsed or refractory mantle cell lymphoma, yet prognosis remains inadequate for many. The choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains a topic of debate in this patient population.
NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners - Leukemia
Abstract NUP98 rearrangements represent a distinct, high-risk subtype of acute myeloid leukemia (AML), particularly in pediatric patients. However, their prevalence, genetic features, and clinical implications in adult AML remain poorly characterized. Using targeted-capture sequencing, we identified 41 cases with NUP98 rearrangements among 1569 AML cases, representing the majority of 44 NUP98-rearranged cases detected across 4753 myeloid neoplasms.
Effect of Prophylactic Administration of Foscarnet for HHV‐6 Encephalitis in Adult Single Cord Blood Transplantation
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description tid70147-sup-0001-TableS1.docx15.2 KB Supporting File 1: tid70147-sup-0001-TableS1.docx tid70147-sup-0002-TableS2.docx14.5 KB Supporting File 2: tid70147-sup-0002-TableS2.docx References 1, “Cord Blood 2.0: State of the Art and Future Directions in Transplant Medicine,” Blood Research 54 (2019): 7–9. 2, “Alternative Donors: Cord Blood for Adults,” Seminars in Hematology 53 (2016): 65–73.
Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy | Bone Ma
Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia | Bone Marrow Transplantation
Abstract Choosing an optimal alternative donor is an important clinical concern in allogeneic hematopoietic cell transplantation (HCT). In Japan, single-unit umbilical cord blood transplantation (UCBT) has been widely used in the last two decades, whereas HCT from HLA-haploidentical related donors (haplo-HCT) has been increasingly used following the advent of posttransplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis.
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia - Bone Marrow Transplantation
Second allogeneic hematopoietic cell transplantation (HCT2) is a useful option for treating relapsed acute myeloid leukemia (AML) after the first allogeneic hematopoietic cell transplantation (HCT1). Performing HCT2 for relapsed AML in complete remission is frequently difficult because of the overall response rate of 40–50% with salvage chemotherapy for relapsed myeloid malignancies after HCT1 [1, 2].
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML - Leukemia
Abstract Venetoclax plus azacitidine (VEN + AZA) is widely used in acute myeloid leukemia (AML). This study explored the role of static and dynamic profiles of mutational clonal burden to predict outcomes by analyzing marrow samples from 228 VEN + AZA treated AML cases at “Pre-treatment” (n = 228), “Best-response” (n = 105), and “Relapse” (n = 27) phases using targeted-capture sequencing.
Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia - Bone Marrow Transplantation Original
The prognostic significance of the internal tandem duplication of FLT3 (FLT3-ITD) and NPM1 mutations is well-recognized in patients with acute myeloid leukemia (AML) treated with chemotherapy [1]. However, consensus regarding their effects on outcomes in those undergoing allogeneic hematopoietic cell transplantation (HCT) remains lacking.
Long‐Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for BCR::ABL1‐Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective Study by Adult CML/MPN and MDS Working Groups of the Japanese Society for Transplantation and
To the Editor, Atypical chronic myeloid leukemia (aCML), BCR::ABL1-negative (also known as myelodysplastic/myeloproliferative neoplasm [MDS/MPN] with neutrophilia) is a rare hematological disorder with increased numbers of neutrophils in the bone marrow and peripheral blood [1]. aCML typically has a very poor prognosis, with median survival of approximately 2 years [2].
Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma | Bone Marrow Transplantation
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for relapsed or refractory non-Hodgkin lymphoma (R/R NHL). Allo-HSCT using post-transplant cyclophosphamide (PTCY-haplo) and umbilical cord blood transplantation (uCBT) are important donor options in the absence of matched related siblings. However, the data comparing these two donor sources in R/R NHL are limited.
Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data | Bone Marrow Transplantation
Abstract Prognosis for patients undergoing hematopoietic cell transplantation (HCT) has been improving. Short-term survival information, such as crude survival rates that consider deaths immediately after the transplantation, may not be sufficiently useful for assessing long-term survival. Using the data of the Japanese HCT registry, the net survival rate of patients who survived for a given period was determined according to age, disease, and type of transplant.
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era | Bone Marrow Transplantation
Abstract The impact of letermovir (LTV)—an anti-cytomegalovirus (CMV) drug—on human herpesvirus-6 (HHV-6) encephalitis is unclear. We hypothesized that LTV prophylaxis may increase the incidence of HHV-6 encephalitis by reducing anti-CMV therapies after allogeneic hematopoietic stem cell transplantation (HSCT).
The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
1 INTRODUCTION The development of new drugs for multiple myeloma (MM), such as proteasome inhibitors, immunomodulatory drugs, and particularly monoclonal antibodies, has dramatically improved the overall survival (OS) of patients with MM.1, 2 Even in the modern era, however, autologous stem cell transplantation (ASCT) remains the mainstay for transplant-eligible MM patients.3-5 In previous studies, we demonstrated that the OS of patients with MM after ASCT has improved over time along with...
Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma | Bone Marrow Transplantation
Abstract Data comparing HLA-haploidentical donors and HLA-matched sibling donors (MSDs) in peripheral blood stem cell transplantation (PBSCT) for lymphoma are scarce. We retrospectively analyzed 465 patients with lymphoma aged 16 years or older who underwent PBSCT using haploidentical donors with post-transplant cyclophosphamide (PTCy-haplo) (n = 166) or MSDs with calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis (n = 299).
The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia - Bone Marrow Transplantation
Abstract This study aimed to address the prognostic impact of center experience based on the data of 7821 adults with acute myeloid leukemia who underwent allogeneic hematopoietic cell transplantation (HCT) from 2010 to 2019 in Japan, where medical care was provided within a uniform healthcare system.
Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry
INTRODUCTION Aplastic anaemia (AA) is a form of bone marrow (BM) failure caused by the immune system attacking healthy BM cells. The diagnosis of AA is based on the exclusion of other conditions that may cause pancytopenia.1 Myelodysplastic neoplasms (MDS) are a group of BM failure diseases characterised by morphological dysplastic changes in BM cells.
KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis - Bone Marrow Transplantation
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability Analyzed data will be shared via emails to the corresponding author.
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide - Bone Marrow Transplantation
Abstract There is limited evidence regarding the association between graft-versus-host disease (GVHD) and reduced relapse in patients who undergo allogeneic hematopoietic stem cell transplantation from haploidentical donors (haplo-HSCT) using post-transplant cyclophosphamide (PTCY). We investigated the association between GVHD and transplant outcomes in 938 patients who received haplo-HSCT using PTCY.
Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy
CONFLICT OF INTEREST STATEMENT None of the authors has a relevant conflict of interest to this research. Supporting Information Filename Description bjh19041-sup-0001-FigureS1.epsPS document, 16.8 MB Figure S1. bjh19041-sup-0002-FigureS2.epsPS document, 16.8 MB Figure S2. bjh19041-sup-0003-FigureS3.epsPS document, 16.8 MB Figure S3. bjh19041-sup-0004-FigureS4.epsPS document, 16.8 MB Figure S4. bjh19041-sup-0005-TableS1.xlsxExcel 2007 spreadsheet , 12.8 KB Table S1.
Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy | Bone Marrow Transplantation
Authors and Affiliations Department of Hematology, Osaka International Cancer Institute, Osaka, Japan Shigeo Fuji Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan Akitoshi Hakoda & Ayumi Shintani Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Junya Kanda Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan Takahiro Fukuda Hematology...
External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia - Bone Marrow Transplantation
Abstract This study aimed to validate the utility of the transplant conditioning intensity (TCI) score in 1714 patients with acute myeloid leukemia (AML) undergoing allogeneic bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT) and assess its applicability to 753 patients with AML undergoing umbilical cord blood transplantation (UCBT) both during first complete remission.
Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma - Bone Marrow Transplantation
Authors and Affiliations Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan Yoshitaka Inoue Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan Satoko Morishima & Shouhei Tomori Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan Koji Kato & Yasuo Mori Department of...
Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study | Bone Marrow Transplantation
Authors and Affiliations Department of Hematology, Imamura General Hospital, Kagoshima, Japan Masahito Tokunaga, Nobuaki Nakano & Atae Utsunomiya Department of Hematology, Osaka International Cancer Institute, Osaka, Japan Shigeo Fuji Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL KAJIGAYA, Tokyo, Japan Atsushi Wake Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan Ayumu...
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study
Abstract Large differences in patient and transplant backgrounds make it difficult to identify consistent prognostic factors of unrelated cord blood transplantation (UCBT) among different populations. Thus, we performed a collaborative study between Eurocord/ALWP-EBMT and JSHCT/JDCHCT. Adults with acute leukaemia who underwent a single UCBT were eligible. In total, 3764 and 1027 patients of the JSHCT/JDCHCT and Eurocord/ALWP-EBMT registries, respectively, were included.
Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis
Abstract A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Junya
Contact Junya, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack